Page last updated: 2024-12-07

wr 158122

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

WR 158122: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID98652
CHEMBL ID268584
SCHEMBL ID5619636
MeSH IDM0059931

Synonyms (37)

Synonym
2,4-diamino-6-(2-naphthalenylsulfonyl)quinazoline
2,4-diamino-6-(2-naphthyl-sulfonyl)-quinazoline
brn 0763154
2,4-quinazolinediamine, 6-(2-naphthalenylsulfonyl)-
2,4-diamino-6-(2'-naphthyl)sulfonylquinazoline
nsc 157388
wr-158,122
nsc157388
wr 158122
2,4-diamino-6-(2-naphthylsulfonyl)quinazoline
2, 6-(2-naphthalenylsulfonyl)-
mls002920661 ,
51123-83-2
nsc-157388
NCI60_001140
smr001798248
CHEMBL268584
gnf-pf-2448 ,
6-naphthalen-2-ylsulfonylquinazoline-2,4-diamine
TCMDC-137192 ,
wr-158122
wr 158,122
unii-3lr92usv18
5-25-13-00133 (beilstein handbook reference)
3lr92usv18 ,
SCHEMBL5619636
GBVQWZXJDIIUCC-UHFFFAOYSA-N
2,4-diamino-6-(naphth-2-ylsulfonyl)quinazoline
cid_98652
6-(2-naphthalenylsulfonyl)quinazoline-2,4-diamine
bdbm83720
[2-amino-6-(2-naphthylsulfonyl)quinazolin-4-yl]amine
DTXSID40199144
6-(2-naphthylsulfonyl)-2,4-quinazolinediamine
2,4-diamino-6-(2-naphthylsulfonyl) quinazoline
2,4-diamino-6-(2-naphthyl-sulfonyl)quinazoline
PD162556

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
glp-1 receptor, partialHomo sapiens (human)Potency15.84890.01846.806014.1254AID624417
ClpPBacillus subtilisPotency39.81071.995322.673039.8107AID651965
TDP1 proteinHomo sapiens (human)Potency6.70880.000811.382244.6684AID686978; AID686979
Smad3Homo sapiens (human)Potency17.78280.00527.809829.0929AID588855
67.9K proteinVaccinia virusPotency2.00850.00018.4406100.0000AID720579; AID720580
IDH1Homo sapiens (human)Potency8.19950.005210.865235.4813AID686970
DNA dC->dU-editing enzyme APOBEC-3F isoform aHomo sapiens (human)Potency25.11890.025911.239831.6228AID602313
Glycoprotein hormones alpha chainHomo sapiens (human)Potency1.00004.46688.344810.0000AID624291
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Dihydrofolate reductaseRattus norvegicus (Norway rat)IC50 (µMol)0.00400.00060.35076.2000AID58160
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
endoribonuclease toxin MazFEscherichia coli str. K-12 substr. MG1655EC50 (µMol)99.00003.96009.515717.4000AID588481; AID588502
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (14)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell population proliferationGlycoprotein hormones alpha chainHomo sapiens (human)
hormone-mediated signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
regulation of signaling receptor activityGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of steroid biosynthetic processGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of cell migrationGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid gland developmentGlycoprotein hormones alpha chainHomo sapiens (human)
luteinizing hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone signaling pathwayGlycoprotein hormones alpha chainHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIGlycoprotein hormones alpha chainHomo sapiens (human)
negative regulation of organ growthGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone secretionGlycoprotein hormones alpha chainHomo sapiens (human)
thyroid hormone generationGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (3)

Processvia Protein(s)Taxonomy
hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
protein bindingGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone activityGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
extracellular regionGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
Golgi lumenGlycoprotein hormones alpha chainHomo sapiens (human)
follicle-stimulating hormone complexGlycoprotein hormones alpha chainHomo sapiens (human)
pituitary gonadotropin complexGlycoprotein hormones alpha chainHomo sapiens (human)
extracellular spaceGlycoprotein hormones alpha chainHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (113)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1135039Inhibition of Plasmodium berghei dihydrofolate reductase1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145674Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1145685Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145683Antibacterial activity against sensitive Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135006Antimalarial activity against chloroquine-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135034Antibacterial activity against Shigella sonnei C-10 assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134986Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 40 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135014Antimalarial activity against cycloguanil-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID159583Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 40 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1145675Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID58160Inhibitory activity against dihydrofolate reductase of rat liver1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Inhibition of dihydrofolate reductase: structure-activity correlations of quinazolines based upon molecular shape analysis.
AID1134977Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 2.5 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135028Antimalarial activity against Plasmodium vivax VietnamPalo Alto in po dosed Owl monkey assessed as curative dose compound treated for 7 days in presence of 5 mg/kg sulfadiazine for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID1135024Antimalarial activity against Plasmodium vivax VietnamPalo Alto in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID111801Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 80 mg/kg subcutaneous dose; 5 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1135031Antibacterial activity against Staphylococcus aureus S18713 assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134969Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 2.5 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135023Antimalarial activity against Plasmodium vivax New Guinea Chesson in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134960Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 5 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134965Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 40 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135021Antimalarial activity against Plasmodium falciparum Vietnam Oak Knoll in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135027Antimalarial activity against Plasmodium falciparum Vietnam Smith in po dosed Owl monkey assessed as curative dose compound treated for 7 days in presence of 5 mg/kg sulfadiazine for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135033Antibacterial activity against Escherichia coli Vogel assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135010Antimalarial activity against DDS-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145385Inhibition of liver dihydrofolate reductase (unknown origin)1976Journal of medicinal chemistry, May, Volume: 19, Issue:5
Inhibition of dihydrofolate reductase. Structure-activity correlations of quinazolines.
AID58159The concentration required to inhibit dihydrofolate reductase in rat liver1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
General distance geometry three-dimensional receptor model for diverse dihydrofolate reductase inhibitors.
AID159450Antimalarial activity as survivor numbers at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 20 mg/kg subcutaneous dose after 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID56152Binding energy against Streptococcus faecium dihydrofolate reductase1980Journal of medicinal chemistry, Jun, Volume: 23, Issue:6
Quantitative structure-activity relationships by distance geometry: systematic analysis of dihydrofolate reductase inhibitors.
AID1135017Antimalarial activity against chloroquine-sensitive, pyrimethamine-resistant Plasmodium falciparum Malayan Camp CH/Q infected in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134989Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 5 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID159710Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 80 mg/kg subcutaneous dose over 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1145676Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 to IC50 for sensitive Lactobacillus casei ATCC 74691977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID111795Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 40 mg/kg subcutaneous dose; 5 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1145686Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth in presence of 0.001 ug/ml folinic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID99484Anti tumor activity against L1210 leukemia in tissue culture and the molar concentration required to reduce the number of L1210 cells1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID58164Concentration required for inhibition of rat liver dihydrofolate reductase (DHFR)1983Journal of medicinal chemistry, Jul, Volume: 26, Issue:7
Combined distance geometry analysis of dihydrofolate reductase inhibition by quinazolines and triazines.
AID1134976Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 5 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134982Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 20 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134978Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 1.25 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145679Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 to IC50 for sensitive Pediococcus cerevisiae ATCC 8081977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145677Antibacterial activity against sensitive Pediococcus cerevisiae ATCC 808 assessed as reduction1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1145671Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1134991Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 1.25 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134983Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 10 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145672Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135008Antimalarial activity against cycloguanil-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135012Antimalarial activity against chloroquine-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135020Antimalarial activity against Plasmodium falciparum Malayan Camp CH/Q infected in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134968Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 5 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135032Antibacterial activity against Pseudomonas aeruginosa 28 assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134966Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 20 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145681Antibacterial activity against sensitive Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1134952Antimalarial activity against trophozoite-induced Plasmodium berghei infected in sc dosed mouse assessed as minimum curative dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1132881Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 52 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID159575Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 320 mg/kg subcutaneous dose over 72 hrs1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID56148Binding energy to Streptococcus faecium dihydrofolate reductase1982Journal of medicinal chemistry, Aug, Volume: 25, Issue:8
Quantitative structure-activity relationship by distance geometry: quinazolines as dihydrofolate reductase inhibitors.
AID1145684Antibacterial activity against chlorguanide triazine-resistant Lactobacillus casei ATCC 7469 assessed as reduction in growth in presence of 0.001 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145688Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as active dose required to increase of 100% in mean survival time1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135030Antibacterial activity against Staphylococcus aureus UC-76 assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145682Antibacterial activity against chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 assessed as reduction in growth in presence of 0.002 ug/ml folic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID159444Antimalarial activity as survivor number at day 60 against drug-sensitive Plasmodium berghei infected mice (Mus musculus) at 160 mg/kg subcutaneous dose after 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1134990Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 2.5 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID111803Antimalarial activity against Plasmodium berghei strain in mice (Mus musculus) by parentral route and change in mean survival time in days was determined at 160 mg/kg subcutaneous dose; 5 cured at 60 days postinfection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1134987Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 20 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134981Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as cured at 40 mg/kg, sc single dose1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID111798Antimalarial activity against Plasmodium berghei strain in mice (Mus musculus) by parentral route and change in mean survival time in days was determined at 640 mg/kg subcutaneous dose; 5 cured at 60 days postinfection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1135018Antimalarial activity against chloroquine-resistant, pyrimethamine-sensitive Plasmodium falciparum Vietnam Oak Knoll in Aotus monkey assessed as dose required to >50% cures compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID111807Antimalarial activity against Plasmodium berghei in mice (Mus musculus) by parenteral route and change in mean survival time in days was determined at 320 mg/kg subcutaneous dose; 5 cured at 60 days post infection1987Journal of medicinal chemistry, Nov, Volume: 30, Issue:11
Synthesis and antimalarial and antitumor effects of 2-amino-4-(hydrazino and hydroxyamino)-6-[(aryl)thio]quinazolines.
AID1135016Antimalarial activity against DDS-resistant Plasmodium gallinaceum infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days relative to parent strain1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1146760Inhibition of Streptococcus faecium dihydrofolate reductase using dihydrofolate as substrate1977Journal of medicinal chemistry, Jan, Volume: 20, Issue:1
Quantitative structure-activity relationships of antimalarial and dihydrofolate reductase inhibition by quinazolines and 5-substituted benzyl-2,4-diaminopyrimidines.
AID1145689Antimalarial activity against Plasmodium berghei infected in sc dosed mouse assessed as dose required to survivors for period of 60 days1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135022Antimalarial activity against Plasmodium falciparum Vietnam Smith in po once daily dosed Owl monkey assessed as curative dose compound treated for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134970Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 1.25 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135038Antibacterial activity against Pediococcus cerevisiae assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145673Fold increase in resistance, ratio of IC50 for chlorguanide triazine-resistant Streptococcus faecium ATCC 8043 to IC50 for sensitive Streptococcus faecium ATCC 80431977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135026Antimalarial activity against Plasmodium falciparum Vietnam Oak Knoll in po dosed Owl monkey assessed as curative dose compound treated for 7 days in presence of 5 mg/kg sulfadiazine for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135035Antibacterial activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135037Antibacterial activity against Lactobacillus casei assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135029Antibacterial activity against Streptococcus faecalis MGH-2 assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1132883Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 13 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1135025Antimalarial activity against Plasmodium falciparum Malayan Camp CH/Q infected in po dosed Owl monkey assessed as curative dose compound treated for 7 days in presence of 5 mg/kg sulfadiazine for 7 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1145687Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth in presence of p-aminobenzoic acid1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1145678Antibacterial activity against chlorguanide triazine-resistant Pediococcus cerevisiae ATCC 808 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1134961Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 2.5 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134967Antimalarial activity against trophozoite-induced Plasmodium gallinaceum infected in chick assessed as mean survival time at 10 mg/kg, sc single dose (Rvb = 4 days)1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135004Antimalarial activity against Plasmodium gallinaceum parent strain infected in mouse assessed as dose required to suppress parasitemia by 90% compound treated through gavage for 3 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134988Toxicity in trophozoite-induced Plasmodium gallinaceum infected in chick assessed as death at 10 mg/kg, sc single dose measured within 48 hrs1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1135002Antimalarial activity against Plasmodium gallinaceum infected in mouse assessed as quinine equivalent to dose required to suppress parasitemia by 75% compound treated through gavage for 3 days1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID159589Antimalarial activity as survivor numbers at day 60 for drug-sensitive Plasmodium berghei infected mice (Mus musculus) after 72 hr1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Folate antagonists. 22. Antimalarial and antibacterial effects of 2,4-diamino-6-quinazolinesulfonamides.
AID1145680Antibacterial activity against sensitive Escherichia coli ATCC 10536 assessed as reduction in growth1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Antifolate studies. Activities of 40 potential antimalarial compounds against sensitive and chlorguanide triazine resistant strains of folate-requiring bacteria and Escherichia coli.
AID1135036Antibacterial activity against Streptococcus faecalis assessed as growth inhibition1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1134962Antimalarial activity against trophozoite-induced Plasmodium berghei infected in mouse assessed as change in mean survival time at 1.25 mg/kg, sc single dose after 72 hrs of infection1979Journal of medicinal chemistry, Oct, Volume: 22, Issue:10
Folate antagonists. 15. 2,3-Diamino-6-(2-naphthylsulfonyl)quinazoline and related 2,4-diamino-6-[(phenyl and naphthyl)sulfinyl and sulfonyl]quinazolines, a potent new class of antimetabolites with phenomenal antimalarial activity.
AID1159588Biochemical screen of P. falciparum CDPK42016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159586Biochemical screen of P. falciparum PK62016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159585Biochemical screen of P. falciparum CDPK12016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159589Biochemical screen of P. falciparum MAPK22016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID1159587Biochemical screen of P. falciparum PK72016PloS one, , Volume: 11, Issue:3
Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (66.67)18.7374
1990's0 (0.00)18.2507
2000's2 (9.52)29.6817
2010's4 (19.05)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.07 (24.57)
Research Supply Index3.09 (2.92)
Research Growth Index4.16 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]